Venturi Wealth Management LLC Purchases 219 Shares of TransMedics Group, Inc. (NASDAQ:TMDX)

Venturi Wealth Management LLC raised its position in TransMedics Group, Inc. (NASDAQ:TMDX) by 33.7% during the 3rd quarter, HoldingsChannel.com reports. The institutional investor owned 869 shares of the company’s stock after acquiring an additional 219 shares during the period. Venturi Wealth Management LLC’s holdings in TransMedics Group were worth $136,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors have also recently made changes to their positions in TMDX. Vanguard Group Inc. raised its stake in TransMedics Group by 1.3% in the 1st quarter. Vanguard Group Inc. now owns 1,889,094 shares of the company’s stock valued at $139,680,000 after acquiring an additional 23,979 shares during the period. Driehaus Capital Management LLC raised its position in shares of TransMedics Group by 15.8% in the second quarter. Driehaus Capital Management LLC now owns 1,486,073 shares of the company’s stock valued at $223,832,000 after purchasing an additional 202,867 shares during the period. Allspring Global Investments Holdings LLC lifted its stake in shares of TransMedics Group by 5.3% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 599,116 shares of the company’s stock valued at $94,061,000 after buying an additional 30,092 shares in the last quarter. Price T Rowe Associates Inc. MD boosted its holdings in TransMedics Group by 8.1% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 297,324 shares of the company’s stock worth $21,985,000 after buying an additional 22,223 shares during the period. Finally, Vaughan Nelson Investment Management L.P. purchased a new position in TransMedics Group in the 2nd quarter valued at approximately $39,862,000. Hedge funds and other institutional investors own 99.67% of the company’s stock.

TransMedics Group Stock Performance

NASDAQ TMDX opened at $92.73 on Thursday. The company has a market capitalization of $3.11 billion, a P/E ratio of 98.65 and a beta of 2.08. The company has a debt-to-equity ratio of 2.42, a quick ratio of 7.33 and a current ratio of 8.20. TransMedics Group, Inc. has a 52-week low of $61.98 and a 52-week high of $177.37. The company has a fifty day moving average of $129.09 and a 200-day moving average of $139.89.

TransMedics Group (NASDAQ:TMDX) last issued its quarterly earnings results on Monday, October 28th. The company reported $0.12 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.29 by ($0.17). The firm had revenue of $108.76 million for the quarter, compared to the consensus estimate of $115.00 million. TransMedics Group had a return on equity of 18.74% and a net margin of 8.14%. The company’s revenue for the quarter was up 63.7% on a year-over-year basis. During the same period last year, the firm earned ($0.12) EPS. As a group, equities research analysts predict that TransMedics Group, Inc. will post 1.07 EPS for the current fiscal year.

Insider Buying and Selling at TransMedics Group

In other news, insider Nicholas Corcoran sold 10,000 shares of the company’s stock in a transaction on Tuesday, August 27th. The shares were sold at an average price of $176.02, for a total value of $1,760,200.00. Following the completion of the sale, the insider now owns 21,105 shares of the company’s stock, valued at approximately $3,714,902.10. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In other news, CEO Waleed H. Hassanein sold 8,625 shares of TransMedics Group stock in a transaction dated Monday, September 16th. The stock was sold at an average price of $153.42, for a total value of $1,323,247.50. Following the transaction, the chief executive officer now owns 61,643 shares in the company, valued at approximately $9,457,269.06. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Nicholas Corcoran sold 10,000 shares of the business’s stock in a transaction dated Tuesday, August 27th. The shares were sold at an average price of $176.02, for a total value of $1,760,200.00. Following the completion of the sale, the insider now directly owns 21,105 shares of the company’s stock, valued at approximately $3,714,902.10. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 36,958 shares of company stock worth $5,230,528 over the last ninety days. Insiders own 7.00% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have recently commented on the company. Stephens raised their price target on TransMedics Group from $151.00 to $178.00 and gave the stock an “overweight” rating in a report on Friday, August 2nd. Canaccord Genuity Group cut their target price on TransMedics Group from $169.00 to $109.00 and set a “buy” rating for the company in a research note on Tuesday, October 29th. JPMorgan Chase & Co. reduced their target price on TransMedics Group from $173.00 to $116.00 and set an “overweight” rating for the company in a report on Tuesday, October 29th. Needham & Company LLC lowered their price target on shares of TransMedics Group from $208.00 to $109.00 and set a “buy” rating on the stock in a report on Tuesday, October 29th. Finally, Oppenheimer reduced their price objective on shares of TransMedics Group from $200.00 to $125.00 and set an “outperform” rating for the company in a research note on Tuesday, October 29th. One equities research analyst has rated the stock with a hold rating, nine have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average target price of $144.80.

TransMedics Group Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.